润达医疗
(603108)
| 流通市值：58.04亿 | | | 总市值：58.04亿 |
| 流通股本：6.05亿 | | | 总股本：6.05亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 3,193,709,975.77 | 1,510,505,870.23 | 6,998,529,976.26 | 5,268,459,587.79 |
| 营业收入 | 3,193,709,975.77 | 1,510,505,870.23 | 6,998,529,976.26 | 5,268,459,587.79 |
| 二、营业总成本 | 3,128,160,636.06 | 1,504,546,302 | 7,099,474,285.35 | 5,307,471,760.12 |
| 营业成本 | 2,411,617,499.97 | 1,159,431,877.16 | 5,501,628,423.01 | 4,134,821,387.13 |
| 税金及附加 | 14,351,465.01 | 6,964,559.32 | 29,199,696.24 | 21,422,146.27 |
| 销售费用 | 317,345,469.9 | 156,681,465.68 | 748,601,097.65 | 562,371,124.47 |
| 管理费用 | 188,653,116.01 | 92,875,139.62 | 438,515,506.84 | 303,152,989.12 |
| 研发费用 | 53,206,049.74 | 25,928,682.72 | 108,013,762.47 | 82,554,832.89 |
| 财务费用 | 142,987,035.43 | 62,664,577.5 | 273,515,799.14 | 203,149,280.24 |
| 其中:利息费用 | 137,691,293.12 | 60,939,111.53 | 278,931,171.45 | 208,662,636.08 |
| 其中:利息收入 | 2,290,369.87 | 1,488,229.02 | 10,980,948.03 | 10,040,351.09 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 24,478,851.52 | 12,478,846.42 | 20,794,519.81 | 66,886,817.47 |
| 资产处置收益 | -2,146,048.92 | -1,481,788.22 | 3,119,148.21 | 893,530.01 |
| 资产减值损失(新) | -913,179.76 | -266,653.6 | -208,737,137.88 | -70,339.94 |
| 信用减值损失(新) | -91,770,284.36 | -54,742,104.55 | -196,535,945.86 | -110,956,271.25 |
| 其他收益 | 5,354,034.91 | 2,685,984.03 | 32,047,685.39 | 24,748,191.11 |
| 四、营业利润 | 552,713.1 | -35,366,147.69 | -450,256,039.42 | -57,510,244.93 |
| 加:营业外收入 | 189,192.18 | 178,091.31 | 5,853,029.53 | 3,069,154.88 |
| 减:营业外支出 | 11,268,276.34 | 843,523.79 | 16,234,218.1 | 7,346,697.45 |
| 五、利润总额 | -10,526,371.06 | -36,031,580.17 | -460,637,227.99 | -61,787,787.5 |
| 减:所得税费用 | 50,894,895.1 | 9,942,365.08 | 57,513,652.47 | 64,415,776.3 |
| 六、净利润 | -61,421,266.16 | -45,973,945.25 | -518,150,880.46 | -126,203,563.8 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -61,421,266.16 | -45,973,945.25 | -518,150,880.46 | -126,203,563.8 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -87,866,991.37 | -53,561,218.35 | -548,393,978.51 | -162,691,533.55 |
| 少数股东损益 | 26,445,725.21 | 7,587,273.1 | 30,243,098.05 | 36,487,969.75 |
| 扣除非经常损益后的净利润 | -80,674,008.41 | -53,161,947.11 | -565,822,548.63 | -178,282,052.02 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.15 | -0.09 | -0.91 | -0.27 |
| (二)稀释每股收益 | -0.15 | -0.09 | -0.91 | -0.27 |
| 八、其他综合收益 | 3,066,687.42 | 1,343,539.1 | -10,279,338.19 | -285,439.17 |
| 归属于母公司股东的其他综合收益 | 2,866,084.32 | 1,251,318.78 | -9,811,024.62 | -262,060.32 |
| 九、综合收益总额 | -58,354,578.74 | -44,630,406.15 | -528,430,218.65 | -126,489,002.97 |
| 归属于母公司股东的综合收益总额 | -85,000,907.05 | -52,309,899.57 | -558,205,003.13 | -162,953,593.87 |
| 归属于少数股东的综合收益总额 | 26,646,328.31 | 7,679,493.42 | 29,774,784.48 | 36,464,590.9 |
| 公告日期 | 2026-08-28 | 2026-04-29 | 2026-04-29 | 2025-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |